Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Non-cash Items: 2015-2025

Historic Non-cash Items for Voyager Therapeutics (VYGR) over the last 10 years, with Sep 2025 value amounting to $6.0 million.

  • Voyager Therapeutics' Non-cash Items rose 30.02% to $6.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.0 million, marking a year-over-year increase of 30.02%. This contributed to the annual value of $3.5 million for FY2024, which is 69.34% down from last year.
  • Per Voyager Therapeutics' latest filing, its Non-cash Items stood at $6.0 million for Q3 2025, which was up 2,323.78% from $247,000 recorded in Q2 2025.
  • In the past 5 years, Voyager Therapeutics' Non-cash Items ranged from a high of $29.9 million in Q2 2023 and a low of $247,000 during Q2 2025.
  • Over the past 3 years, Voyager Therapeutics' median Non-cash Items value was $4.8 million (recorded in 2024), while the average stood at $7.6 million.
  • Its Non-cash Items has fluctuated over the past 5 years, first skyrocketed by 405.16% in 2023, then plummeted by 97.39% in 2025.
  • Quarterly analysis of 5 years shows Voyager Therapeutics' Non-cash Items stood at $3.6 million in 2021, then decreased by 24.01% to $2.7 million in 2022, then surged by 311.48% to $11.3 million in 2023, then crashed by 57.16% to $4.8 million in 2024, then soared by 30.02% to $6.0 million in 2025.
  • Its last three reported values are $6.0 million in Q3 2025, $247,000 for Q2 2025, and $499,000 during Q1 2025.